Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast
Jody Vykoukal1, Yihui Chen1, Mingxin Zuo1
1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Selective autophagy of mitochondria is known to promote cancer cell survival and progression, including in triple-negative breast cancer (TNBC). Here, we apply an integrated multi-omics approach together with functional experimental analyses to investigate metabolic adaptations that support mitochondrial quality control in TNBC. We detail a mitochondrial quality control mechanism, complementary to mitophagy, that is enabled by a program of heightened extracellular sphingomyelin salvaging in TNBC coupled with extracellular vesicle-mediated intracellular clearance of mitochondrial damage. Targeting of this onco-metabolic pathway via repurposing of eliglustat, a selective small molecule inhibitor of glucosylceramide synthase, results in ceramide-mediated compensatory mitophagy and cancer cell death in vitro and attenuates tumor growth and prolongs overall survival at clinically achievable doses in orthotopic syngeneic mouse models of TNBC as well as in human cell line-derived xenograft models. Our study defines an unexplored mechanism of aberrant sphingolipid metabolism that underlies an actionable metabolic vulnerability for anti-cancer treatment.
Insights
Triple-negative breast cancer cells survive by salvaging sphingomyelin and clearing mitochondrial damage via extracellular vesicles. Inhibiting this pathway with eliglustat triggers cell death and slows tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Research
Background:
- Selective mitochondrial autophagy, or mitophagy, promotes cancer cell survival and progression, particularly in triple-negative breast cancer (TNBC).
- Understanding metabolic adaptations supporting mitochondrial quality control is crucial for developing novel TNBC therapies.
Purpose of the Study:
- To investigate metabolic adaptations enabling mitochondrial quality control in TNBC.
- To identify and target a novel onco-metabolic pathway involving sphingolipid metabolism.
Main Methods:
- Integrated multi-omics analysis combined with functional experimental validation.
- Investigation of extracellular sphingomyelin salvaging and extracellular vesicle-mediated mitochondrial clearance.
- Pharmacological targeting using eliglustat, a glucosylceramide synthase inhibitor.
Main Results:
- A novel mitochondrial quality control mechanism complementary to mitophagy was identified, involving heightened extracellular sphingomyelin salvaging in TNBC.
- Extracellular vesicle-mediated clearance of mitochondrial damage was observed.
- Eliglustat treatment induced ceramide-mediated compensatory mitophagy, leading to cancer cell death in vitro.
- Eliglustat attenuated tumor growth and prolonged survival in preclinical TNBC models (syngeneic and xenograft).
Conclusions:
- Aberrant sphingolipid metabolism represents an actionable metabolic vulnerability in TNBC.
- Targeting this pathway with eliglustat offers a promising therapeutic strategy for TNBC.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Mitochondrial Membranes
Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Intralumenal Vesicles and Multivesicular Bodies


